IVIG, SCIG and mABs Therapy

The application of Intravenous Immunoglobulin (IVIG), subcutaneous Immunoglobulin (SCIG) and monoclonal antibodies (mABs) represents a new area in treating Long Covid, Post Vac and Chronic Illnesses. These conditions involve complex immune dysregulation and inflammatory responses. 

IVIG and SCIG are a concentrated preparation of immunoglobulins derived from pooled human plasma.

The current official indications include symptoms present in chronic illness and many post-viral conditions: Myo- and Pericarditis, Small Fiber Neuropathy but also acute/severe conditions like Sepsis.

Monoclonal antibodies, designed to target specific components of the immune response, present another avenue for intervention. 

Both IVIG/SCIG and mABs are being investigated for their potential to restore immune homeostasis.

Here is a current study regarding the use of IVIG in Long Covid/Small Fiber Neuropathy: https://www.neurology.org/doi/10.1212/NXI.0000000000200244

Anecdotal note: mABs are designed strain-specific, IVIG/SCIGs are not. To our knowledge there have been no reports of Long Covid/Post Vac patients worsening permanently after IVIG, SCIG or mABs treatment. The only patients our medical team has observed to worsen temporarily after IVIG treatment were patients with symptoms presenting similar to headaches expanding down to the neck area.

Many of the mABs are discontinued or priced at high level, hence IVIG use has become predominant. This is changing with the availability of Evusheld and potentially Kavigale (coming soon).